Research Proqram Leaders Committee (RPLC) - The RPLC meets on the first Thursday of each month to discuss issues relevant to research opportunities and needs within the VICC. The meeting is co-chaired by the Director and Associate Director for Basic Science Research Programs. Other members include all Research Program Leaders and Co-Leaders, the Deputy Director, the Associate Director of Clinical Science Research Programs, the Associate Director for Prevention, Control and Population-Based Research, the Associate Director for Shared Resources, the Associate Director for CCSG Administration, and the Director Emeritus. This is an important forum in which program leaders exchange information about inter- and intra-programmatic research initiatives and provide updates about ongoing high impact research in each of the programs. Planning for new or modified shared resources, recruitments, inter-programmatic collaborations and other activities to enhance the programs occurs during these meetings. Another important charge of the RPLC is to review new requests for membership in VICC and to make recommendations to the Director. Membership applications are submitted detailing the cancer-related activities of prospective members. The RPLC evaluates the application for compliance with VICC membership criteria, the committee then judges the applicant for suitability for assignment to the appropriate research program and a recommendation is made to the Director, who has ultimate authority in appointing members. The RPLC also conducts an annual review of the VICC membership and assesses cancer-relevant funding and publications, program participation and cancer collaborations for each member. The most recent evaluation occurred in the fall of 2008. The RPLC also plays an important role in review of CCSG Pilot Project applications. The RPLC selects reviewers for the applications and ranks the applications after all reviews have been returned. This ranking process is important as most years only 15-20% of submitted applications can be funded.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA068485-18
Application #
8733531
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2014-09-01
Budget End
2015-08-31
Support Year
18
Fiscal Year
2014
Total Cost
$294,523
Indirect Cost
$89,304
Name
Vanderbilt University Medical Center
Department
Type
DUNS #
004413456
City
Nashville
State
TN
Country
United States
Zip Code
37212
Nyhoff, Lindsay E; Clark, Emily S; Barron, Bridgette L et al. (2018) Bruton's Tyrosine Kinase Is Not Essential for B Cell Survival beyond Early Developmental Stages. J Immunol 200:2352-2361
Horvat, Andela; Noto, Jennifer M; Ramatchandirin, Balamurugan et al. (2018) Helicobacter pylori pathogen regulates p14ARF tumor suppressor and autophagy in gastric epithelial cells. Oncogene 37:5054-5065
Funkhouser-Jones, Lisa J; van Opstal, Edward J; Sharma, Ananya et al. (2018) The Maternal Effect Gene Wds Controls Wolbachia Titer in Nasonia. Curr Biol 28:1692-1702.e6
Harris, Nicholas A; Isaac, Austin T; G√ľnther, Anne et al. (2018) Dorsal BNST ?2A-Adrenergic Receptors Produce HCN-Dependent Excitatory Actions That Initiate Anxiogenic Behaviors. J Neurosci 38:8922-8942
Shropshire, J Dylan; On, Jungmin; Layton, Emily M et al. (2018) One prophage WO gene rescues cytoplasmic incompatibility in Drosophila melanogaster. Proc Natl Acad Sci U S A 115:4987-4991
Raybuck, Ariel L; Cho, Sung Hoon; Li, Jingxin et al. (2018) B Cell-Intrinsic mTORC1 Promotes Germinal Center-Defining Transcription Factor Gene Expression, Somatic Hypermutation, and Memory B Cell Generation in Humoral Immunity. J Immunol 200:2627-2639
McDonnell, Wyatt J; Koethe, John R; Mallal, Simon A et al. (2018) High CD8 T-Cell Receptor Clonality and Altered CDR3 Properties Are Associated With Elevated Isolevuglandins in Adipose Tissue During Diet-Induced Obesity. Diabetes 67:2361-2376
Wilson, Andrew J; Stubbs, Matthew; Liu, Phillip et al. (2018) The BET inhibitor INCB054329 reduces homologous recombination efficiency and augments PARP inhibitor activity in ovarian cancer. Gynecol Oncol 149:575-584
Williams, Michelle M; Lee, Linus; Werfel, Thomas et al. (2018) Intrinsic apoptotic pathway activation increases response to anti-estrogens in luminal breast cancers. Cell Death Dis 9:21
Ding, Tianbing; Mokshagundam, Shilpa; Rinaudo, Paolo F et al. (2018) Paternal developmental toxicant exposure is associated with epigenetic modulation of sperm and placental Pgr and Igf2 in a mouse model. Biol Reprod 99:864-876

Showing the most recent 10 out of 2462 publications